Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage

Launched by STONY BROOK UNIVERSITY · Feb 16, 2022

Keywords

ClinConnect Summary

This clinical trial is investigating whether using two medications together (misoprostol and oxytocin) is more effective than using just one medication (oxytocin alone) to prevent early postpartum hemorrhage, which is heavy bleeding after giving birth. Previous studies suggest that using both medications might reduce the chances of this serious condition. The trial aims to see if combining these two drugs can help more women avoid postpartum hemorrhage and to check for any side effects that might occur with the two-drug approach.

To participate in this trial, women must be at least 18 years old and planning to give birth at Stony Brook University Hospital. However, women with certain medical conditions, such as bleeding disorders or allergies to specific medications, will not be eligible. If you join the study, you will either receive the combination of both medications or the standard treatment of just oxytocin, and you will be monitored to see how well they work and if there are any side effects. This research could help improve care for new mothers in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • - All women 18 years and older admitted to delivery at Stony Brook University hospital who agree to participate in the study
• Exclusion Criteria:
• • Women under 18 years old
• • Women with known coagulation disorders
• • Women with planned cesarean hysterectomy
• • Women with known placental accreta spectrum disorders
• • Women with known allergy to prostaglandins